Amalgamated Financial’s Maravai LifeSciences MRVI Stock Holding History

Amalgamated Financial’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$893K	Buy	+25,327	New	+$849K	0.01%	1227

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Amalgamated Financial's MRVI Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Maravai LifeSciences (MRVI) in Q1 2022: 25,327 shares worth $893K. The stake represents 0.01% of the portfolio and ranks #1227 among its holdings.

235 funds tracked by Wall St. Rank hold MRVI as of Q1 2022.

Amalgamated Financial held 25,327 shares of Maravai LifeSciences worth $893K as of Q1 2022.
Maravai LifeSciences was a new Amalgamated Financial position in Q1 2022.
Maravai LifeSciences made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1227 holding.
235 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.